Design and development of a soft corticosteroid, loteprednol etabonate

Inhaled Steroids in Asthma: Optimizing Effects in the Airways

Volumn , Issue , 2016, Pages 541-564

  Bodor, Nicholas ^a   Buchwald, Peter ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85121179896     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780203908532-24     Document Type: Chapter

References (89)

1. Holgate ST. The epidemic of allergy and asthma. Nature 1999; 402 (suppl):B2-B4.
2. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326:862-866.
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157:S1-S53.
4. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999; 402 (suppl):B31-B38.
5. Monder C, Bradlow HL. Cortoic acids: explorations at the frontier of corticosteroid metabolism. Recent Progr Horm Res 1980; 36:345-400.
6. Bodor N. The soft drug approach. Chemtech 1984; 14(1): 28-38.
7. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000; 20:58-101.
8. Bodor N. Novel approaches for the design of membrane transport properties of drugs. In: Roche EB, ed. Design of Biopharmaceutical Properties through Prodrugs and Analogs. Washington, DC: Academy of Pharmaceutical Sciences, 1977:98-135.
9. Bodor N, Kaminski JJ, Selk S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J Med Chem 1980; 23:469-474.
10. Bodor N, Kaminski JJ. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents. J Med Chem 1980; 23:566-569.
11. Bodor N, Woods R, Raper C, Kearney P, Kaminski J. Soft drugs. 3. A new class of anticholinergic agents. J Med Chem 1980; 23:474-480.
12. De Winter ML. Strategy in drug research. The second IUPAC-IUPHAR Symposium, held from 25 to 28 August 1981 in Noordwijkerhout, The Netherlands. Trends Pharmacol Sci 1982; 3:132-134.
13. Bodor N. Soft drugs: strategies for design of safer drugs. In: Buisman JAK, ed. Strategy in Drug Research. Proceedings of the 2nd IUPAC-IUPHAR Symposium on Research, Noordwijkerhout, The Netherlands. Amsterdam: Elsevier, 1982:137-164.
14. Bodor N. Soft drugs: strategies for design of safer drugs. In: Briot M, Cautreels W, Roncucci R, eds. Metabolisme et Conception Medicaments: Quo Vadis? Proceedings of Symposium at Montpellier, France, November 26-27, 1981. Montpellier: CLIN MIDY, 1983:217-251.
15. Gillette JR. Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds. Drug Metab Rev 1979; 10:59-87.
16. Mannering GJ. Hepatic cytochrome P-450-linked drug-metabolizing systems. In:Testa B, Jenner P, eds. Concepts in Drug Metabolism Part B. New York: Marcel Dekker, Inc, 1981:53-166.
17. Augustinsson K-B. Multiple forms of esterase in vertebrate blood plasma. Ann NY Acad Sci 1961; 94:844-860.
18. Krisch K. Carboxylic ester hydrolases. In: Boyer PD, ed. The Enzymes. Vol. 5. New York: Academic Press, 1971:43-69.
19. Heymann E. Hydrolysis of carboxylic esters and amides. In: Jakoby WB, Bend JR, Caldwell J, eds. Metabolic Basis of Detoxication. New York: Academic Press, 1982:229-245.
20. Walker CH, Mackness MI. Esterases: problems of identification and classification. Biochem Pharmacol 1983; 32:3265-3569.
21. Williams FW. Clinical significance of esterases in man. Clin Pharmacokin 1985; 10:392-403.
22. Leinweber F-J. Possible physiological roles of carboxylic ester hydrolases. Drug Metab Rev 1987; 18:379-439.
23. Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998; 38:257-288.
24. Quon CY, Mai K, Patil G, Stampfli HF. Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 1988; 16:425-428.
25. Minagawa T, Kohno Y, Suwa T, Tsuji A. Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 1995; 49:1361-1365.
26. Buchwald P, Bodor N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 1999; 42:5160-5168.
27. Buchwald P, Bodor N. Structure-based estimation of enzymatic hydrolysis rates and its application in computer-aided retrometabolic drug design. Pharmazie 2000; 55:210-217.
28. Korolkovas A. Essentials of Medicinal Chemistry. 2nd ed. New York: Wiley, 1988.
29. Bodor N. Soft drugs. In: Dulbecco R, ed. Encyclopedia of Human Biology. Vol. 7. San Diego: Academic Press, 1991:101-117.
30. Bodor N, Buchwald P. Drug targeting via retrometabolic approaches. Pharmacol Ther 1997; 76:1-27.
31. Laurent H, Gerhards E, Wiechert R. New biologically active pregnan-21-oic acid esters. J Steroid Biochem 1975; 6:185-192.
32. Kapp JF, Koch H, Töpert M, Kessler H-J, Gerhards E. Unterschungen zur Pharmakologie von 6a-Fluor-11b-hydroxy-16a-methyl-3, 20-dioxo-1, 4-pregnadiene-21-säure-butylester (Fluocortin-butylester). Arzneim Forsch 1977; 27:2191-2202.
33. Lee HJ, Soliman MRI. Anti-inflammatory steroids without pituitary-adrenal suppresion. Science 1982; 215:989-991.
34. Heiman AS, Ko D-H, Chen M, Lee HJ. New steroidal anti-inflammatory antedrugs:methyl 3, 20-dioxo-9a-fluoro-11b, 17a, 21-trihydroxy-1, 4-pregnadiene-16a-carboxylate and methyl 21-acetyloxy-3, 20-dioxo-11b, 17a-dihydroxy-9a-fluoro-1, 4-pregnadiene-16a-carboxylate. Steroids 1997; 62:491-499.
35. Ueno H, Maruyama A, Miyake M, Nakao E, Nakao K, Umezu K, Nitta I. Synthesis and evaluation of antiinflammatory activities of a series of corticosteroids 17a-esters containing a functional group. J Med Chem 1991; 34:2468-2473.
36. Suzuki T, Sato E, Tada H, Tojima Y. Examination of local anti-inflammatory activties of new steroids, hemisuccinyl methyl glycolates. Biol Pharm Bull 1999; 22:816-821.
37. Biggadike K, Angell RM, Burgess CM, Farrell RM, Hancock AP, Harker AJ, Irving WR, Loannou C, Procopiou PA, Shaw RE, Solanke YE, Singh OMP, Snowden MA, Stubbs RJ, Walton S, Weston HE. Selective plasma hydrolysis of glucocorticoid g-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem 2000; 43:19-21.
38. Graffner-Nordberg M, Sjödin K, Tunek A, Hallberg A. Synthesis and enzymatic hydrolysis of esters, constituting simple models of soft drugs. Chem Pharm Bull 1998; 46:591-601.
39. Ong JTH, Poulsen BJ, Akers WA, Scholtz JR, Genter FC, Kertesz DJ. Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide. Arch Dermatol 1989; 125:1662-1665.
40. Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Möllmann H, Derendorf H. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996; 36:938-941.
41. Thorsson L, Dahlström K, Edsbäcker S, Källén A, Paulson J, Wirén J-E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43:155-161.
42. Bodor N. Soft steroids having antiinflammatory activity. Belgian Patent, BE889, 563 (Cl. CO7J), 1981.
43. Bodor N. The application of soft drug approaches to the design of safer corticosteroids. In: Christophers E, Kligman AM, Schöpf E, Stoughton RB, eds. Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs. New York: Raven Press Ltd, 1988:13-25.
44. Bodor N, Varga M. Effect of a novel soft steroid on the wound healing of rabbit cornea. Exp Eye Res 1990; 50:183-187.
45. Druzgala P, Hochhaus G, Bodor N. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem 1991; 38:149-154.
46. Druzgala P, Wu W-M, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991; 10:933-937.
47. Alberth M, Wu W-M, Winwood D, Bodor N. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory corticosteroid. J Biopharm Sci 1991; 2:115-125.
48. Bodor NS, Kiss-Buris ST, Buris L. Novel soft steroids: effects on cell growth in vitro and on wound healing in the mouse. Steroids 1991; 56:434-439.
49. Bodor N, Bodor N, Wu W-M. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res 1992; 11:525-530.
50. Bodor N, Loftsson T, Wu W-M. Metabolism, distribution, and transdermal permeability of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992; 9:1275-1278.
51. Hochhaus G, Chen L-S, Ratka A, Druzgala P, Howes J, Bodor N, Derendorf H. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 1992; 81:1210-1215.
52. Loftsson T, Bodor N. The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids. Adv Drug Deliv Rev 1994; 14:293-299.
53. Bodor N, Murakami T, Wu W-M. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats-for safer treatment of gastrointestinal inflammation. Pharm Res 1995; 12:869-874.
54. Bodor N, Wu W-M, Murakami T, Engel S. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 1995; 12:875-879.
55. Reddy IK, Khan MA, Wu WM, Bodor NS. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocul Pharmacol Ther 1996; 12:159-167.
56. Buris LF, Bodor N, Buris L. Loteprednol etabonate, a new soft steroid is effective in a rabbit acute experimental model for arthritis. Pharmazie 1999; 54:58-61.
57. Little RJ, Bodor N, Loftsson T. Soft drugs based on hydrocortisone: the inactive metabolite approach and its application to steroidal antiinflammatory agents. Pharm Res 1999; 16:961-967.
58. Raizman M. Corticosteroid therapy of eye disease: fifty years later. Arch Ophthalmol 1996; 114:1000-1001.
59. Dickerson JE, Jr., Dotzel E, Clark AF. Steroid-induced cataract: New perspectives from in vitro and lens culture studies. Exp Eye Res 1997; 65:507-516.
60. Heyns K, Koch W. Über die Bildung eines Aminozuckers aus d-Fruktose und Ammoniak. Z Naturforsch B 1952; 7B:486-488.
61. Bucala R, Fishman J, Cerami A. Formation of covalent adducts between cortisol and 16a-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci USA 1982; 79:3320-3324.
62. Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 1984; 74:1803-1810.
63. Bucala R, Gallati M, Manabe S, Cotlier E, Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res 1985; 40:853-863.
64. Urban RC, Jr., Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986; 31:102-110.
65. Bodor N. Design of novel soft corticosteroids. In: Korting HC, Maibach HI, eds. Topical Glucocorticoids with Increased Benefit /Risk Ratio. Basel: Karger, 1993:11-19.
66. Bodor N. Designing safer drugs based on the soft drug approach. Trends Pharmacol Sci 1982; 3:53-56.
67. Druzgala P, Bodor N. Regioselective O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17a-alkoxy, a 17a-(1-alkoxyethyloxy), a 17a-alkoxymethyloxy, or a 17a-methylthiomethyloxy function. Steroids 1991; 56:490-494.
68. Bodor N. Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 1984; 3:449-469.
69. Bodor N. Prodrugs versus soft drugs. In: Bundgaard H, ed. Design of Prodrugs. Amsterdam:Elsevier, 1985:333-354.
70. Bodor N. Designing safer ophthalmic drugs. In: van der Goot H, Domany G, Pallos L, Timmerman H, eds. Trends in Medicinal Chemistry 88. Proceeding of the Xth International Symposium on Medicinal Chemistry. Amsterdam: Elsevier, 1989:145-164.
71. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993; 9:157-165.
72. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998; 7:266-269.
73. Howes J, Novack GD. Failure to detect systemic levels and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1998; 14:153-158.
74. Bartlett JD, Howes JF, Ghormley NR, Amos JF, Laibovitz R, Horwitz B. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993; 12:313-321.
75. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997; 23:31-36.
76. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol 1997; 123:455-464.
77. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1997; 123:791-797.
78. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998; 102:251-255.
79. Shulman DG, Lothringer HL, Rubin JM. A randomized, double-masked, placebocontrolled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999; 106:362-369.
80. Beehler C, Bodner B, Bowman B, Cooke D, Crabb JL, DeBarge LR, Donnenfeld E, Estopinal M, Fox K, Kastl P, Olander K, Sharpe E, Shofner R, Stahl J, Stevenson D, Stewart W, Walters T, Gill S, Howes J, Lawson C, Smerick M, Zaccardelli D, Fazio R, Novack GD, Crockett RS, Hart K. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 1998; 105:1780-1786.
81. Stewart R, Horwitz B, Howes J. A double-masked, placebo controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. J Cataract Refr Surg 1998; 24:1480-1489.
82. Caldwell D, Cohen GR, Davis J, DeBarge LR, Foley J, Foster CS, Fox K, Friedlaender M, John G, Kaufman A, Nozik R, Olander K, Ostrov C, Raizman M, Rosenbaum J, Sall K, Sheppard J, Stewart D, Stewart W, Tauber J, Trocme S, Zimmerman P, Howes J, Coultas S, Crockett RS, Novack GD, Strahlman ER, Neumann R. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999; 127:537-544.
83. Noble S, Goa KL. Loteprednol etabonate. Clinical potential in the management of ocular inflammation. BioDrugs 1998; 10:329-339.
84. Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie 2000; 55:178-183.
85. Poppe H, Szelenyi I. Effects of topically administered loteprednol etabonate on allergic rhinitis in Brown-Norway rats and on late phase allergic eosinophilia in guinea pigs. N-S Arch Pharmacol 1998; 358 (suppl 1):R327.
86. Poppe H, Marx D, Heer S, Szelenyi I. Effects of loteprednol etabonate on TNFa and GM-CSF release in vitro and on late phase allergic eosinophilia in guinea pigs administered intratracheally as a dry powder. Am J Respir Crit Care Med 1998; 157(suppl. 3):A522.
87. Poppe H, Küsters S, Szelenyi I. Effect of AWD 12-281, a new selective PDE4-inhibitor, loteprednol, and beclomethasone in models of allergic rhinitis and airway inflammation in Brown-Norway rats. Am J Respir Crit Care Med 1999; 159(suppl 3): A95.
88. Poppe H, Marx D, Szelenyi I. Comparison of the therapeutic effects of loteprednol, beclomethasone and fluticasone in preclinical models of allergic rhinitis and airway inflammation and on thymus weight in rats. Eur Respir J 1999; 14(suppl 30):158s.
89. Szelenyi I, Hochhaus G, Heer S, Küsters S, Marx D, Poppe H, Engel J. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today 2000; 36:313-320.